Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

98P - Cationic dendrimers as prospective vehicles of therapeutic nucleic acids into tumor cells: Approaches, advantages and challenges


06 Mar 2023


Cocktail & Poster Display session


Nadezhda Knauer


Annals of Oncology (2023) 8 (1suppl_2): 100898-100898. 10.1016/esmoop/esmoop100898


N. Knauer1, E. Pashkina1, O. Boeva1, A. Aktanova1, V. Arkhipova2, M. Meschaninova2, J.P. Majoral3, A. Nickel4, S. Muhammad4, D. Hänggi5, U.D. Kahlert6, V. Kozlov1, E. Apartsin3

Author affiliations

  • 1 Laboratory Of Clinical Immunopathology, FSBSI Research Institute of Fundamental and Clinical Immunology, 630099 - Novosibirsk/RU
  • 2 Laboratory Of Rna Chemistry, The Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of ICBFM RAS, 630090 - Novosibirsk/RU
  • 3 Laboratoire Chimie De Coordination, CNRS, 31077 - Toulouse/FR
  • 4 Neurovascular Research Unit, HHU - Heinrich-​Heine-Universität Düsseldorf, 40225 - Düsseldorf/DE
  • 5 Clinic Of Neurosurgery, HHU - Heinrich-​Heine-Universität Düsseldorf, 40225 - Düsseldorf/DE
  • 6 University Clinic For General, Visceral And Vascular Surgery, Universitätsklinikum Magdeburg A. ö. R. - Medizinische Fakultaet, 39120 - Magdeburg/DE


This content is available to ESMO members and event participants.

Abstract 98P


Challenges of nanomedicine in oncology require therapeutic tools to affect metabolic pathways in the target cells. Therapeutic nucleic acids (NAs) are promising instruments as siRNAs target them selectively, while microRNAs can reach several targets. However, oligonucleotides suffer from rapid nuclease degradation in biological media. Cationic dendrimers – highly symmetric hyperbranched molecules – can be efficient vehicles. In the current work we studied challenges of using polycationic phosphorus and carbosilane dendrimers and their complexes with oligonucleotides (dendriplexes).


Different tumor models were used: Jurkat (single-cells suspension culture in serum-containing media), BTSC233, JHH520, NCH644, GBM1 (glioblastoma cancer stem cells (GSCs) as neurospheres in serum-free medium), U87 (“standard” glioblastoma culture). Human PBMCs and iPSCs were used as non-tumor controls. We used miR-34, synthetic inhibitor of miR-21 and siRNA against LYN kinase (siLyn) as therapeutics. Such biological effects as internalization, cytotoxicity (incl. comparison to standard chemodrugs), apoptosis induction, expression of surface markers, related to interactions with immune microenvironment (PD-L1, TIM-3, CD47), LYN-expression were investigated.


Dendrimers have their own cytotoxic effects on tumor cells, which are comparable or superior to standard chemodrugs; in some models the toxic effect on tumor cells was higher than on non-tumor cells. Moreover, GSCs showed higher sensitivity to molecules. Cationic dendrimers efficiently delivered NAs into tumor cells. Dendriplexes showed antitumor effects: decrease of cell viability, apoptosis induction. Dendrimers and dendriplexes affected the expression of PD-L1 and TIM-3, which could be a sign of cell stress. siLyn-dendriplexes decreased tumor cell viability but did not change significantly LYN expression. Patterns of changes strongly depended on the cell type and cultivation mode.


We showed promising antitumor activity of cationic dendrimers and their complexes with therapeutic NAs. However, further investigations of the impact of different cell type and model features in view of pre-clinical testing is to be performed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


European Cooperation in Science and Technology CA17140.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.